Effects of the Cornelian Cherry Supplementation on the Selected Physiological Parameters in Marathon Runners

NCT07194720 | Completed

• 1 other identifier: DEREN.23.25
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

Growing body of evidence indicates favorable effects of Cornus mas (Cornelian cherry) supplements on cardiometabolic risk, including the improvement of HDL and glycemic indices, in line with vascular benefits. Experimental data feature bioactives from Cornelian cherry as potential modulators of vascular function and blood pressure, plausibly via endothelial nitric oxide-related pathways, with possible downstream effects on autonomic reflex control; nevertheless, such links in humans remain poorly explored to date, especially in terms of endurance training and hypoxia tolerance. In this cross-over, placebo-controlled study, a group of healthy amateur long-distance runners underwent two stages of a four-week dietary intervention (separated by four weeks of washout period), receiving Cornelian cherry lyophilisate or placebo. Each supplementation stage was accompanied by the comprehensive evaluation of the cardio-respiratory parameters and endothelial function.

Conditions

Healthy

Keywords

Cornus mas L.; systemic vascular resistance; peripheral chemoreflex; endurance training; nitric oxide; endothelium; autonomic nervous system; blood pressure

Outcome Measures

Primary Outcomes (2)

• Systemic vascular resistance

  Resting systemic vascular resistance, evaluated non-invasively with a finger cuff-based device.

  From the beginning to the end of a supplementation period at 4 weeks.

• Office blood pressure values (mean, systolic, diastolic)

  Resting arterial blood pressure values (mean, systolic, diastolic), measured continuously with a non-invasive, finger cuff-based device.

  From the beginning to the end of a supplementation period at 4 weeks.

Secondary Outcomes (2)

• Peripheral chemoreflex sensitivity

  From the beginning to the end of a supplementation period at 4 weeks.

• eNOS expression

  From the beginning to the end of a supplementation period at 4 weeks.

Study Arms (2)

Cornus mas lyophilisate

EXPERIMENTAL

Dietary Supplement: Cornus mas lyophilisate

placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo

Interventions

Cornus mas lyophilisate DIETARY_SUPPLEMENT

Participants receiving a Cornus mas (Cornelian cherry) lyophilisate for 4 weeks.

Cornus mas lyophilisate

Placebo DIETARY_SUPPLEMENT

Participants receiving a starch- and sugar-based placebo for 4 weeks.

placebo

Eligibility Criteria

• Age: 45 Years - 75 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• age above 45 years

You may not qualify if:

• chronic disease of the nervous, cardiovascular or respiratory system
• disease of the digestive system, including history of the intestinal surgery, inflammatory bowel disease, celiac disease, lactose intolerance and other malabsorption disorders
• blood pressure-lowering treatment within the past year
• tobacco smoking within the past year
• antibiotic/probiotic treatment and laxative/prokinetic usage in three months preceding the anticipated enrollment

Sponsors & Collaborators

• Wroclaw Medical University: lead
• Wrocław University of Environmental and Life Sciences: collaborator

Study Sites (1)

Wroclaw Medical University

Wroclaw, Lower Silesian Voivodeship, 50-376, Poland

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: September 18, 2025
• First Posted: September 26, 2025
• Study Start: September 15, 2021
• Primary Completion: April 21, 2022
• Study Completion: April 21, 2022
• Last Updated: October 1, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

PL (1)